FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Merck, Schering's Vytorin fails trial

The gig is up, the news is out. Merck and Schering-Plough announced the results of its big ENHANCE trial this morning. And, as observers had begun to suspect, the study showed that, when it comes to arterial thickness, there was no significant difference between treatment with generic simvastatin (Zocor) and Vytorin, which combines Zocor and Zetia (ezetimibe).

The study did show a big advantage in cholesterol-lowering with the combo treatment, Vytorin. Patients saw their "bad" cholesterol drop by 58 percent with Vytorin versus 41 percent with Zocor alone. But other studies haven't shown a difference in patient outcomes, such as fewer heart attacks or strokes.

As you know, Merck and Schering embarked on this study hoping that Vytorin could trounce Zocor, and therefore elbow aside not only Zocor's generic competitors but other statins, too. But after the data came in, the companies delayed its release, and even made a feint toward changing the trial's primary endpoint. Critics denounced that idea, and the streets were buzzing with speculation about the trial results. (It didn't help that the companies were accused of withholding damaging data from other Vytorin studies.) Apparently, Merck and Schering decided that the truth, while none too impressive, was better than the speculation.

- see the release from Merck
- read a brief story from Dow Jones
- read some cardiologists' speculation in the Wall Street Journal Health Blog

Related Articles:
Merck, Schering left trial chief out. Report
Schering CEO defends Vytorin decisions. Report
Merck, Schering backpedal on Vytorin. Report

More stories about Merck   Schering-Plough   Statins   Zocor   ENHANCE trial   ENHANCE  

Comments

I am a heart patient, and I am currently taking VYTORIN. I had a heart attack five months ago and had a stent inserted into one coronary arteries(LAD). I have no "knee jerk" plans to overreact and take myself off VYTORIN. I'm reasonable enough to know how to interpret the inconclusive drug trial results of Enhance. VYTORIN lowered LDL and CRP in the study, and given the very high statin dose (80 mg) used in both treatment groups, it would probably require a much larger patient population size and/or time duration to show a marginal improvement in that primary end point. My conclusion was that the study design wouldn't allow for a significant difference either way in the artery thickness results. Besides, letting the hysterical, publicity crazy, anti-corporate types scare me off a good cholesterol drug for my coronary condition would be fool hardy on my part.

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 23 + 66?
To combat spam, please solve the math question above.